Exon 19 deletion association with progression-free survival compared to L858R mutation at exon 21 in treatment with first-line EGFR-TKIs: A meta-analysis of subgroup data from eight phase III randomized controlled trials.
Wenhua Liang
No relevant relationships to disclose
Jin Sheng
No relevant relationships to disclose
Xuan Wu
No relevant relationships to disclose
Yaxiong Zhang
No relevant relationships to disclose
Shiyang Kang
No relevant relationships to disclose
Li Zhang
Consultant or Advisory Role - AstraZeneca (U); Pfizer (U); Roche (U)
Honoraria - AstraZeneca; Lilly; Roche
Research Funding - AstraZeneca; Aventis; Roche